| 摘要 |
The whole formulation contains known factors which have been shown to have a definite action on our various intended interventions that aim at the complex blocking of the individual inductive/multiplicative carcinogenic processes, which are by themselves complex. By the use of butyric acid, celecoxib, fenretinide, DMFO and nebivolol, the whole complex ôpillö can control the individual developmental, mutagenic effects and other multiplicative effects of the carcinogenic course in the target population of the formulation. The action of IGF-I and II, III, ODC, COX-2, prostanoids (PGP2, PGE2, 6-ketoPGF 1a], oncogenes C-Fos and C-Jun is known. The bioavailability of the formulation [as decomposable in the intestine in general, due to its structure] with a coating and sustained-release components therein, ensures the targeted action and a reduction of the polypod potential, an advantageous effect particularly for people with a related family history [FAP] who have been diagnosed for polypods, have an increased expression of the responsible factors [IGF-1, II, III] or have already been subjected to surgery [once, twice or already subjected to enterotomy etc.]. State of the art The aim and use of the individual materials-factors, or something similar, in the present context has not been known in the state of the art. |
